Key result
Ramipril reduced resting thrombin-antithrombin complex (TAT) and tended to reduce fibrinogen in patients with mild-to-moderate essential hypertension.
Why the study?
Does ramipril reduce blood coagulation markers in subjects with mild-to-moderate essential hypertension?
RCT
Does ramipril reduce blood coagulation markers in subjects with mild-to-moderate essential hypertension?
Ramipril reduces thrombin generation in patients with mild-to-moderate hypertension, which may partly explain its protective effect against thromboembolic complications.
Antihypertensive treatment reduces the risk of thromboembolic events in hypertension. The aim of this study was to examine the influence of angiotensin-converting enzyme inhibition on blood coagulation in subjects with mild-to-moderate essential hypertension. Fibrinogen, thrombin-antithrombin complex (TAT) and Factor VII were determined in plasma at rest and after a mental stress test following placebo for 6 weeks, or ramipril for 6 weeks or 6 months. Ramipril reduced resting TAT, and tended to reduce fibrinogen; Factor VII remained unchanged. Mental stress increased fibrinogen, but did not alter TAT or Factor VII activity. The reduced thrombin generation in patients taking ramipril may explain in part why angiotensin-converting enzyme inhibitors reduce thromboembolic complications in patients with cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Ekholm et al. (2002) conducted an RCT in Mild-to-moderate essential hypertension. Ramipril vs. Placebo was evaluated on Fibrinogen, thrombin-antithrombin complex (TAT) and Factor VII in plasma at rest and after a mental stress test. Ramipril reduced resting thrombin-antithrombin complex (TAT) and tended to reduce fibrinogen in patients with mild-to-moderate essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: